These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 33946916)

  • 21. Advances in the development of hybrid anticancer drugs.
    Fortin S; Bérubé G
    Expert Opin Drug Discov; 2013 Aug; 8(8):1029-47. PubMed ID: 23646979
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in therapy for solid tumors: potential for overcoming drug resistance in vivo with molecular targeting agents.
    Kim R; Toge T
    Surg Today; 2004; 34(4):293-303. PubMed ID: 15052442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anticancer activities, structure-activity relationship, and mechanism of action of 12-, 14-, and 16-membered macrolactones.
    Wang R
    Arch Pharm (Weinheim); 2021 Sep; 354(9):e2100025. PubMed ID: 34138486
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Research Progress in Reversal of Tumor Multi-drug Resistance via Natural Products.
    Guo Q; Cao H; Qi X; Li H; Ye P; Wang Z; Wang D; Sun M
    Anticancer Agents Med Chem; 2017 Nov; 17(11):1466-1476. PubMed ID: 29034843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
    Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
    Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overcoming Resistance to Platinum-Based Drugs in Ovarian Cancer by Salinomycin and Its Derivatives-An In Vitro Study.
    Michalak M; Lach MS; Antoszczak M; Huczyński A; Suchorska WM
    Molecules; 2020 Jan; 25(3):. PubMed ID: 31991882
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Antiproliferative Activity of Ferrocene Derivatives against Drug- Resistant Cancer Cell Lines: A Mini Review.
    Li L; Ma L; Sun J
    Curr Top Med Chem; 2021; 21(19):1756-1772. PubMed ID: 34323188
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent advances of podophyllotoxin/epipodophyllotoxin hybrids in anticancer activity, mode of action, and structure-activity relationship: An update (2010-2020).
    Xiao J; Gao M; Sun Z; Diao Q; Wang P; Gao F
    Eur J Med Chem; 2020 Dec; 208():112830. PubMed ID: 32992133
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery and Development of Macrolides as Anticancer Agents.
    Liu R; Hou Y; Gu Y
    Curr Top Med Chem; 2021; 21(18):1657-1673. PubMed ID: 34315371
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Peroxisome Proliferator-Activated Receptors and their Ligands in Cancer Drug- Resistance: Opportunity or Challenge.
    Yousefi B; Zarghami N; Samadi N; Majidinia M
    Anticancer Agents Med Chem; 2016; 16(12):1541-1548. PubMed ID: 26845135
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resistance against novel anticancer metal compounds: differences and similarities.
    Heffeter P; Jungwirth U; Jakupec M; Hartinger C; Galanski MS; Elbling L; Micksche M; Keppler B; Berger W
    Drug Resist Updat; 2008; 11(1-2):1-16. PubMed ID: 18394950
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metallodrugs in Targeted Cancer Therapeutics: Aiming at Chemoresistance- related Patterns and Immunosuppressive Tumor Networks.
    Petanidis S; Kioseoglou E; Salifoglou A
    Curr Med Chem; 2019; 26(4):607-623. PubMed ID: 29149832
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Abnormal saccharides affecting cancer multi-drug resistance (MDR) and the reversal strategies.
    Wang M; Chen W; Chen J; Yuan S; Hu J; Han B; Huang Y; Zhou W
    Eur J Med Chem; 2021 Aug; 220():113487. PubMed ID: 33933752
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EMICORON: A multi-targeting G4 ligand with a promising preclinical profile.
    Porru M; Zizza P; Franceschin M; Leonetti C; Biroccio A
    Biochim Biophys Acta Gen Subj; 2017 May; 1861(5 Pt B):1362-1370. PubMed ID: 27838395
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overview on Anticancer Drug Design and Development.
    Olgen S
    Curr Med Chem; 2018; 25(15):1704-1719. PubMed ID: 29189124
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and biochemical characterization of new phenothiazines and related drugs as MDR reversal agents.
    Schmidt M; Teitge M; Castillo ME; Brandt T; Dobner B; Langner A
    Arch Pharm (Weinheim); 2008 Oct; 341(10):624-38. PubMed ID: 18816589
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 1,3,5-Triazine-azole Hybrids and their Anticancer Activity.
    Guo H; Diao QP
    Curr Top Med Chem; 2020; 20(16):1481-1492. PubMed ID: 32156236
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nanomedicines as emerging platform for simultaneous delivery of cancer therapeutics: new developments in overcoming drug resistance and optimizing anticancer efficacy.
    Hussain Z; Arooj M; Malik A; Hussain F; Safdar H; Khan S; Sohail M; Pandey M; Choudhury H; Ei Thu H
    Artif Cells Nanomed Biotechnol; 2018; 46(sup2):1015-1024. PubMed ID: 29873531
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tubulin-targeting agents in hybrid drugs.
    Breen EC; Walsh JJ
    Curr Med Chem; 2010; 17(7):609-39. PubMed ID: 20088764
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.